The theme of this year’s scientific program highlights how scientific progress—driven by interdisciplinarity and partnership across sectors of the cancer community—enables increasingly precise strategies for the prevention and treatment of cancer.

Don’t miss notable Professional Development Sessions, Educational Sessions and Methods Workshops, and more, say Program Committee Chairs Paul S. Mischel, MD, FAACR, and Alice T. Shaw, MD, PhD, FAACR.

A record 265 clinical trials abstracts—from proof-of-concept studies to phase III results—will be presented during this year’s AACR Annual Meeting.

The Discovery Science Plenary will focus on the latest research on the evolution of drug resistance, the role of cancer cell heterogeneity and plasticity, and novel strategies to detect and target residual disease.

The latest scientific and clinical innovations for hematologic malignancies will be showcased at the AACR Annual Meeting 2026, with sessions highlighting discovery science advances and how they are being rapidly translated into patient care.

The Regulatory Science and Policy track and the Science and Health Policy track will provide attendees with an opportunity to hear from and interact with key staff from the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH), as well as patient advocates and leaders from industry and academia.

Awards and lectures during the Annual Meeting will honor scientists, clinicians, and physician-scientists who have made significant contributions to the understanding of the diagnosis, prevention, and treatment of cancer.